The Effect of Counseling on Willingness to Use a Hypothetical Medication and Perceptions of Medication Safety by Bitonti, Michael
The Effect of Counseling on Willingness to Use a Hypothetical Medication  
and Perceptions of Medication Safety 
 
Michael Bitontia 
Payal Patela 
Rebecca Dickinsonb 
Peter Knappc 
Susan J. Blalockd 
 
aEshelman School of Pharmacy, University of North Carolina at Chapel Hill  
bSchool of Healthcare, University of Leeds, Leeds, UK 
cDepartment of Health Sciences and the Hull York Medical School, University of York, York, 
UK 
dPharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North 
Carolina at Chapel Hill  
 
 
 
 
 
 
 
 
 
 
 
Honors Student: Michael Bitonti 
Honors Mentor: Dr. Susan Blalock 
Abstract 
Background: Poor medication adherence is an ongoing issue, and contributes to increased 
hospitalizations and healthcare costs. Although most adverse effects are rare, the perceived risk 
of adverse effects may contribute to low adherence rates.  
Objectives: The objective of this study was to determine how adverse effect likelihood and 
pharmacist counseling on adverse effect prevention affects individuals’: (1) willingness to use a 
hypothetical medication and (2) perceptions of medication safety. 
Methods:  This study used a 3x3 experimental design. Participants (n=601) viewed a 
hypothetical scenario asking them to imagine being prescribed an anti-asthma medication that 
could cause fungal infections of the throat. Participants were randomized to 1 of 9 scenarios that 
differed on: probability of developing an infection (5%, 20%, no probability mentioned) and 
whether they were told how to reduce the risk of infection (no prevention strategy discussed, 
prevention strategy discussed, prevention strategy discussed with explanation for how it works). 
Participants were recruited through Amazon Mechanical Turk.  
Results: Participants were less willing to take the medication (F=12.86, p<0.0001) and 
considered it less safe (F=13.11, p<0.0001) when the probability of fungal infection was 
presented as 20% compared to 5% or when no probability information was given. Participants 
were more willing to take the medication (F=11.78, p<0.0001) and considered it safer (F=11.17, 
p<0.0001) when a prevention strategy was given. Finally, there was a non-statistically significant 
interaction between the probability and prevention strategy information such that provision of 
prevention information reduced the effect of variation in the probability of infection on both 
willingness to use the medication and perceived medication safety. 
Conclusions: Optimal risk communication involves more than informing patients about possible 
adverse effects. Pharmacists could potentially improve patient acceptance of therapeutic 
recommendations, and allay medication safety concerns, by counseling about strategies patients 
can implement to reduce the perceived risk of adverse effects.  
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Introduction 
 It is estimated that about 50% of the United States population has used at least one 
prescription medication within the previous month, and roughly 22% has used three or more.1 
However, adherence to medications continues to be a major issue. A recent study found that 18% 
of cardiac prescriptions were not filled by patients four months after a major coronary event.2 
Other research has found that only 37% of patients were adherent to statin therapy and only 66% 
to medications used in diabetes.3,4 High levels of medication adherence for long-term conditions 
can reduce rates of hospitalization and lower overall healthcare costs.3,5 A recent Cochrane 
Review on improving medication adherence found that the most beneficial strategies were highly 
complex and involved consistent follow-up, but provided only marginal benefit in adherence 
rates.6 Thus, the optimal strategy for increasing medication adherence remains unknown. 
 The World Health Organization identifies five categories of factors contributing to 
medication nonadherence: economic, health-system, patient-related, condition-related, and 
therapy-related. Among therapy-related factors, adverse effects of the medication are a major 
obstacle.7 The presence of adverse effects has been shown to decrease adherence to a wide 
variety of medications, including glucocorticoids and antidepressants.8,9 Nearly all medications 
carry the risk of unwanted adverse effects, with varying degrees of likelihood and severity; 
however, most adverse effects are relatively rare or can be mitigated with proper counseling and 
monitoring. For instance, medications that cause stomach upset are often recommended to be 
taken with food to prevent irritation to the GI tract and the resultant nausea.  
Pharmacists can play a significant role in preventing adverse effects from occurring in 
their patients. Including a pharmacist on inter-disciplinary teams conducting patient rounds in an 
Intensive Care Unit has been shown to significantly reduce adverse effects, and discharge 
counseling with a pharmacist has been shown to lower the rate of preventable adverse 
medication-related events following hospital admission.10,11 In addition, pharmacists can play a 
leading role in increasing medication adherence. A recent study found medication reviews and 
follow-up telephone calls with a pharmacist increased adherence to lipid-lowering therapies.12 
Another study found that implementation of a pharmacist-led asthma management service in 
community pharmacies led to improvements in the use of preventative asthma medications.13 
Other research has shown implementation of a pharmacist-driven medication therapy 
management program to increase cardiovascular medication use, while also improving 
cardiovascular risk factors such as systolic and diastolic blood pressure.14 However, little 
research has examined the effect of patient-pharmacist counseling concerning medication risks 
specifically. 
The concept of “risk” is multidimensional.15 With respect to medication risk 
communication, two types of information are especially important for pharmacists to provide: (1) 
the probability of experiencing specific adverse effects and (2) strategies patients can implement 
to reduce the risk of experiencing these effects. Past research has demonstrated that numerical 
adverse effect information is easier for patients to accurately comprehend compared to non-
numerical information.16,17 Patients tend to overestimate the likelihood of adverse effects when 
non-numeric, qualitative descriptors (e.g., common, rare) are used to communicate risk 
likelihood instead of, or in addition to, numerical information (e.g., 10% of patients; 1 in 10 
patients) alone.18,19 Overestimates of risk likelihood can make patients less willing to take a 
medication.16,20    
In a previous study by this research team that was guided by fuzzy trace theory (FTT),21-23 
it was demonstrated that simply informing individuals that a specific adverse effect may occur 
without providing any indication of the probability of occurrence can reduce willingness to use 
the medication and that this effect can be mitigated by providing numeric probability 
information.24 Briefly, FTT is a dual process model of memory reasoning and development. It 
suggests that when individuals are exposed to a meaningful stimulus, they encode two types of 
representations in memory: a specific verbatim representation that captures the exact 
words/numbers conveyed and one or more gist representations that capture the essential bottom 
line meaning of the information. Moreover, past research has found that when people are making 
judgments and decisions, they tend to rely on the gist representations that have been stored in 
memory in response to previously presented information, rather than the verbatim 
representations.23 Thus, the findings from the research team’s previous study suggested that 
when individuals are told that a medication can cause a particular adverse effect without being 
given any probability information, they tend to form a categorical gist representation (e.g, the 
medication can cause harm), leading to risk avoidance (e.g., reduced willingness to use the 
medication); whereas, providing numerical probability information allows individuals to form 
somewhat more precise, ordinal gist representations (e.g., the risk of the medication causing 
harm is small).   
In the study reported in this paper, findings from the research team’s previous study were 
followed up by examining the possibility that unconditional estimates of risk probability (5% 
versus 20%) may be less meaningful and, consequently, have less impact on judgment and 
decision making, when patients are counseled about precautions they can take to reduce risk.  It 
was hypothesized that: 
(1) Individuals will be less willing to use a hypothetical asthma medication (and consider the 
medication less safe) when told that the medication can cause an adverse effect (i.e., fungal 
infection of the throat) without being given any information concerning risk probability 
versus being informed that the likelihood of the adverse effect is 5% or 20%;    
(2) Individuals will be most willing to use the medication and consider it most safe when 
counseling on how to prevent the adverse effect is provided; and 
(3) There will be an interaction between the probability and prevention information such that, 
among individuals counseled on how to prevent the adverse effect, willingness to use the 
medication and perceptions of medication safety will not be affected by the probability of the 
adverse effect. 
Materials and Methods 
To recruit participants, a link was posted to an Internet-based survey on Amazon 
Mechanical Turk (AMT) (www.mturk.com).25 AMT is an internet crowdsourcing marketplace 
where registered users sign up and are able to complete various tasks requiring human 
intelligence for payment. The title of the survey link was “Answer a survey about prescription 
medication information.” The first screen of the survey informed individuals that they were 
being asked to participate in a research study. To obtain informed consent, individuals were 
required to click a button indicating they agreed to participate in the study. The study was 
approved by the Institutional Review Board at the University of North Carolina at Chapel Hill. 
Participants were adults aged 18 years or older and living in the United States. There 
were no other study inclusion or exclusion criteria. A total of 633 Mechanical Turk workers 
accessed the link to the survey, which was administered via Qualtrics® software, and agreed to 
participate in the study. However, 32 of these individuals failed an attention check question that 
appeared as the second question in the survey and these participants were removed from the 
sample, leaving 601 study participants. The attention check question instructed participants to 
select “Somewhat likely” as the response to the question. Selecting any other response invoked a 
skip pattern within Qualtrics that prevented the individual from completing the remainder of the 
survey. This was done to prevent robots from completing the survey. The survey required 
approximately five minutes to complete. All participants were paid fifty US cents for completing 
the survey. All data was collected on June 1, 2015.  
Experimental Materials 
The study used a 3 x 3 experimental research design. An experimental research design 
was used to enhance the internal validity of the study. All participants read a brief, hypothetical 
scenario that began as follows:  
“Imagine you have recently been experiencing episodes of wheezing and shortness of 
breath. You visit your family doctor and he tells you that you have asthma. He assures 
you that asthma is treatable and writes you a prescription for an inhaler called Cradulox. 
The directions say ‘inhale one puff twice daily.’ Your doctor refers you to your local 
pharmacy. The pharmacist fills your prescription, explains how to use the inhaler, and 
states that it can cause fungal infections in the throat.”   
The next portion of the scenario differed across experimental groups. The two experimental 
factors manipulated were (1) probability of developing a fungal infection (i.e., low probability, 
high probability, no probability mentioned) and (2) strategy for preventing fungal infections (i.e., 
no prevention strategy discussed, prevention strategy discussed, prevention strategy discussed 
including an explanation of how the prevention strategy reduces the risk of experiencing a fungal 
infection) (Table 1). Participants in the low probability group were told fungal infections occur 
in 5% of patients who use the inhaler; whereas, participants in the high probability group were 
told fungal infections occur in 20% of inhaler users. Participants in the no probability group were 
simply told the inhaler can cause fungal infections. With respect to prevention information, 
participants in the group that received a prevention strategy were told that rinsing their mouth out 
with water after inhaler use can reduce the risk of getting a fungal infection. Participants in the 
group receiving an additional explanation were told that the medication can get stuck in the back 
of the throat and allow fungi to grow, but water helps to wash the medication away (Table 1). In 
all groups, the scenario ended with the following statement: “The pharmacist tells you that there 
are five refills available on the prescription, and to call the pharmacy if you have any questions.” 
After reading the scenario, participants answered seven questions concerning their perception of 
the safety and effectiveness of the hypothetical medication. Participants were able to refer to the 
scenario while answering the questions. 
The medication described in the scenario, Cradulox, is completely fictional. This was 
done to avoid potential biases amongst participants who may have used other medications in the 
past or know others who have. Asthma was chosen as the disease state for the study because it is 
a common disorder, affecting about 40 million people in the United States, including children 
and young adults as well as older individuals.26 Fungal infection was the adverse effect chosen 
for the scenario to ensure clinical relevance because it is an actual adverse effect common to 
many asthma inhalers.  
Measures 
 Two primary and four secondary outcome variables were assessed. Measures used to 
assess these variables were used in a previous study.24 Results from that study support the 
construct validity of the measures.  
Primary Outcome Variables.  
The primary outcome variables were: (1) willingness to take the medication and (2) 
perceived medication safety. Willingness to take the medication was assessed by asking: “If you 
had asthma and your doctor prescribed this medication for you, how likely is it that you would 
take it?” Participants answered on a 7-point scale ranging from Very Unlikely to Very Likely. 
Participants were also asked: “What is the most important reason for how likely or unlikely you 
would be to take this medication?” The following options were provided: (a) the adverse events 
are not very serious, (b) any serious adverse events are very unlikely, (c) prefer to avoid taking 
medications and will do something else, (d) a lot of people will get fungal infections and I don’t 
want to be one of them, (e) I would like to get rid of the wheezing and shortness of breath, and (f) 
none of the above. This measure was modeled after a question developed by Peters et al.16 
Perceived medication safety was assessed by asking: “How safe or dangerous is this 
medication?” Participants answered on a 7-point scale ranging from Very Safe to Very 
Dangerous. 
Secondary Outcome Variables.   
Four secondary outcome variables were assessed. First, participants were asked to 
respond to the following statement: “The potential benefits of taking this medication outweigh 
the potential risks.” Responses were recorded on a 7-point scale ranging from Strongly Agree to 
Strongly Disagree. Next, participants were asked, “If you had asthma and took this medication, 
how likely is the medication to help you?” Responses were recorded on a 7-point scale ranging 
from Very Likely to Very Unlikely. The final two variables used the same response scale, and 
were as follows: “If you had asthma and took this medication, how likely is the medication to 
cause side effects?” and “How likely are you to recommend this medication to somebody else 
with asthma?” The latter variable was included because people taking medications often make 
recommendations to friends and family members regarding their own experience with different 
medications, especially concerning effectiveness and adverse effects. 
Demographics.  
The following demographic information was assessed: age, gender, race, education, and 
status as a healthcare provider. Healthcare provider status was assessed to ensure that these 
individuals were not overrepresented in the sample, as they likely have greater knowledge of 
both asthma and anti-asthma medications compared to the general public, which could bias study 
findings. In addition, participants were asked to rate their own overall health, with the options 
being poor, fair, good, very good, or excellent. They were also asked whether they were 
currently taking a prescription medication regularly and whether they had ever had a serious side 
effect from a medication. 
Manipulation Check Questions.  
The final three items in the survey were designed as manipulation checks. Participants 
were not able to view the scenario when answering these questions. First, participants were 
asked: “If 100 people used Cradulox, how many do you think would develop a fungal infection 
of the throat.” Second, participants were asked to respond to the following statement: “There are 
things that people can do to reduce the risk of developing a fungal infection when using 
Cradulox.” Responses were recorded on a 7-point scale ranging from Strongly Agree to Strongly 
Disagree. Finally, participants were asked, “Which of the following is most likely to reduce the 
risk of developing a fungal infection when using Cradulox?” The available choices were (a) 
taking the medication with food, (b) rinsing your mouth out with cool water following use, (c) 
using the medication at night prior to bedtime, and (d) none of the above. 
Statistical Analysis 
 All analyses were completed using PC-SAS version 9.4 (SAS Institute Inc., 2013). 
Descriptive statistics were used to summarize the participant characteristics. Student t-tests and 
chi-square tests were conducted to determine if the experimental groups differed with respect to 
any of the demographic characteristics assessed. To determine the effectiveness of the 
experimental manipulations, the percentage of participants in the low and high probability 
conditions who responded correctly to the question asking, “If 100 people used Cradulox, how 
many do you think would develop a fungal infection of the throat?” were calculated (Note: 
Because this analysis assessed participant recollection of the probability information included in 
the experimental manipulation, participants who received no probability information were not 
included in this analysis). The “correct” answer corresponded to participants’ group assignment 
and differed for those in the low and high probability conditions (i.e. 5 out of 100 people or 20 
out of 100 people were considered correct answers, respectively). The percentage of participants 
in each group who correctly responded that the risk of fungal infections could be reduced by 
rinsing one’s mouth out with cool water following use was also calculated. Linear regression was 
used to assess the effect of the two experimental conditions (i.e. probability of fungal infections 
and prevention information to reduce risk) on the primary and secondary outcome variables. A 
separate regression model was run for each outcome variable. Each model included a term 
indexing the multiplicative interaction between the two experimental conditions. If the 
interaction term was not statistically significant, the model was rerun with the interaction term 
deleted. Significant main effects were followed up using the Newman-Keuls method to evaluate 
between group differences while controlling for the inflation of Type I error when making 
multiple comparisons.27 Power analyses indicated that a sample size of 601 provides over 80% 
power to detect a small sized effect (SD=0.2) with alpha (2-tailed) set at 0.05.28  
Results 
Demographics 
 The mean age of participants (n = 601) was 33 years (SD = 10.9) and most identified as 
white (78.2%), male (60.1%), and 52.1% had a bachelor’s degree or higher. Participants reported 
their health as poor (1.8%), fair (9.3%), good (29.6%), very good (41.8%), or excellent (17.5%). 
Only 22 participants (3.7%) identified themselves as a healthcare professional. About a quarter 
(26.8%) of participants reported using a regular prescription medication, and 16% reported 
having experienced a serious side effect from a medication. None of the participant 
characteristics differed significantly across the experimental conditions.  
Manipulation Checks 
 A total of 169 (87.6%) participants in the high probability group correctly answered that 
20 out of 100 people would develop a fungal infection when using Cradulox. Likewise, 179 
(86.9%) participants in the low probability group correctly answered that 5 out of 100 people 
would develop an infection. Among participants who were not given any probability 
information, the median probability estimate was 5.0 (Mean = 12.4, SD = 15.3, IQR=3.0-15.0).  
Participants given prevention information or prevention information plus an explanation 
were more likely to agree that there are things people can do to reduce the risk of developing a 
fungal infection when using Cradulox, with means of 5.3 and 5.4, respectively, compared to 2.9 
in the no prevention information group (F (2,598)=322.38, p < 0.0001). Almost all participants 
who were given either prevention information (96.7%) or prevention information plus an 
explanation (97.5%) correctly indicated that the risk of developing a fungal infection while using 
Cradulox could be reduced by rinsing one’s mouth with cool water following use. Of the 
participants given no prevention information, 38.7% answered correctly. 
Assessment of Interactions 
 The interaction between the two experimental conditions (probability of fungal infection 
and prevention information) was not statistically significant for any of the primary or secondary 
outcome variables. However the interaction terms approached statistical significance for both of 
the primary outcome variables: willingness to take the medication (F(4,592)=1.83, p=0.12) and 
perceived medication safety (F(4,592)=1.68, p=0.15)). Therefore, to explore the nature of these 
possible interactions, the sample was stratified by the type of prevention information provided 
(i.e., none, prevention information only, prevention information plus explanation). As shown in 
Figure 1, among individuals who were given no prevention information, participants who were 
told that the risk of fungal infection was 20% reported being less willing to take the medication 
and perceived the medication as less safe compared to those who were told that the risk of fungal 
infection was 5% (Willingness to Take: Means ± SE = 3.61 ± 0.20 versus 4.79 ± 0.19, p < 
0.0001, respectively; Medication Safety: Means ± SE= 3.45 ± 0.15 versus 4.32 ± 0.13, p < 
0.0001). Similarly, among individuals who were given prevention information combined with an 
explanation, participants who were told that the risk of fungal infection was 20% reported being 
less willing to take the medication and perceived the medication as less safe compared to those 
who were told that the risk of fungal infection was 5% (Willingness to Take: Means ± SE = 4.40 
± 0.20 versus 5.08 ± 0.17, p = 0.01, respectively; Medication Safety: Means ± SE= 3.90 ± 0.15 
versus 4.47 ± 0.14, p =.01). However, among individuals who were given prevention information 
only, there was little difference between participants who were told that the risk of fungal 
infection was 20% versus 5% on either of these variables (Willingness to Take: Means ± SE = 
4.66 ± 0.17 versus 4.98 ± 0.14, p= 0.15, respectively; Medication Safety: Means ± SE= 4.17 ± 
0.13 versus 4.46 ± 0.11, p =0.10).  
Main Effect of Probability Information 
 Linear regression analysis showed that probability of occurrence was a significant 
predictor of willingness to take the medication (F(2,596) = 12.86, p < 0.0001) and perceived 
medication safety (F(2,596) = 13.11, p < 0.0001) (see Table 2). Consistent with study 
hypotheses, participants were significantly less willing to take the medication when a high 
adverse effect probability was given compared to a low probability or no probability. Participants 
were significantly more likely to perceive the medication as safe in the low probability condition 
compared to the high probability and no probability condition.  Linear regression analyses 
showed that probability was also a significant predictor of the belief that medication benefits 
outweigh risks (F(2,596) = 9.55, p < 0.0001), likelihood of the medication helping (F(2,596) = 
3.63, p < 0.05), likelihood of the medication causing side effects (F(2,596) = 45.2, p < 0.0001), 
and likelihood of recommending the medication to others (F(2,596) = 9.2, p = 0.0001). 
Participants in the high probability condition were less likely than those in the other two groups 
to agree that benefits outweigh the risks and that the medication was less likely to help. 
Participants in the low probability condition thought the medication was less likely to cause side 
effects and were more likely to recommend it to others compared to participants in the other two 
groups (see Table 2). 
Main Effect of Prevention Strategy Information 
 Linear regression analysis showed that prevention strategy information was a significant 
predictor of willingness to take the medication (F(2,596) = 11.78, p < 0.0001) and perceived 
medication safety (F(2,596) = 11.17, p < 0.0001) (Table 3). Consistent with study hypotheses, 
participants were significantly less willing to take the medication when no prevention strategy 
was given compared to prevention information with or without an explanation. Participants 
perceived the medication as least safe when no prevention strategy was given and safest when 
prevention strategy information was given. Participants who received a prevention strategy plus 
an explanation perceived the medication as safer than those who received no information but less 
safe than those who received prevention information only. Linear regression analyses also 
showed that prevention strategy information was a significant predictor for the belief that 
medication benefits outweigh risks (F(2,596) = 12.03, p < 0.0001) and the likelihood of 
recommending the medication to others (F(2,596) = 7.61, p = 0.0005). Participants not given any 
prevention information were less likely to consider that the benefits of the medication outweigh 
the risks compared to participants in the other two groups. Participants not given any prevention 
information were also significantly less likely to recommend the medication to others compared 
to participants in the other two groups. There were no significant differences among the three 
groups for perceived likelihood of the medication helping or the likelihood of experiencing 
medication side-effects (see Table 3). 
Reasons for Willingness to Take the Medication 
 Table 4 shows the reasons participants gave for being likely or unlikely to use the 
medication. Only three of the six reasons revealed significant differences between groups. 
Participants in the low probability condition were more likely to select any serious adverse 
events are very unlikely as their reason (x2(2) = 12.39, p = 0.002) compared to participants in the 
other two probability groups. Participants in the high probability condition were more likely than 
either of the other conditions to select a lot of people will get fungal infections and I don’t want 
to be one of them (x2(2) = 16.96, p = 0.0002). Participants given prevention information plus an 
explanation were most likely to choose the adverse events are not very serious as their reasoning 
for how likely or unlikely they would be to take the medication, followed by participants given 
only prevention information (x2(2) = 18.08, p < 0.0001). Participants not given any prevention 
information were more likely to choose a lot of people will get fungal infections and I don’t want 
to be one of them as their reasoning (x2(2) = 18.97, p < 0.0001). There were no significant 
between group differences among participants selecting prefer to avoid taking medications and 
will do something else, I would like to get rid of the wheezing and shortness of breath, and none 
of the above. 
Discussion 
 The vast majority of past research on medication risk communication has focused on how 
probabilistic information is best conveyed. Much less attention has been given to other risk 
dimensions that may be equally or more important such as severity and controllability.15,29,30 The 
study reported in this paper was designed to address this knowledge gap by examining how 
information concerning precautions patients can take to reduce the risk of adverse effects may 
influence willingness to use a medication and perceptions of medication safety.  This focus was 
based on two factors. First, if patients adopt recommended precautions while using a prescribed 
medication, their objective risk of experiencing adverse effects should be reduced and this may 
be reflected in perceived risk as well.  Second, educating patients about safety precautions is 
likely to enhance perceptions of the extent to which the risk is controllable. This is important 
because past research has demonstrated an inverse association between perceived controllability 
and perceived risk.31 
Most study hypotheses were at least partially supported. First, it was predicted that 
individuals who were told that a hypothetical medication can cause fungal infections of the throat 
without being given any probability information would be less willing to take the medication and 
perceive it as less safe compared to individuals who were told that the risk was either 5% or 
20%. However, it was found that the mean for all of the outcome variables in the group that was 
given no probability information fell between the means observed in the high and low probability 
groups. Further, although individuals who received no probability information reported being as 
likely to take the medication as individuals in the low probability group, they perceived the 
medication as less safe. These findings suggest that, while patients may agree to take a 
medication even if they are not told the probability of adverse effects, they might have residual 
concerns about medication safety that, in real-life situations, could manifest as premature 
medication discontinuation or lower adherence rates.32-38 Research suggests that health care 
providers rarely provide quantitative probability information when counseling patients.29 In 
addition, most of the written information provided to patients in the United States simply lists 
possible adverse effects, without providing any probability information. However, written 
medication information provided to patients in the European Union does include this type of 
information.39 Research is needed to determine if these different types of information formats 
have differential effects on real-life judgment and decision-making. 
Second, participants who received information concerning the prevention of fungal 
infections, with or without an explanation of how the prevention strategy worked, reported being 
more willing to use the medication than participants who were not given this type of information. 
However, participants who received an explanation of how the prevention strategy worked rated 
the medication as less safe compared to those who were given prevention information alone. 
This may be because the explanation made the possibility of experiencing a fungal infection 
more salient to participants as they completed the questionnaire. Nonetheless, participants who 
received the explanation were more likely than those in the other two groups to indicate that their 
primary reason for being willing to take the medication was that the adverse effects were not 
very serious. These findings highlight the complexity of the risk communication process, and 
there is no previous research that has examined the impact of precaution information on 
medication risk perception. Thus, more research is needed to better understand how patients 
interpret information concerning the prevention of adverse events and how they utilize this 
information when making judgments and decisions concerning medication use. 
Third, although not statistically significant, the findings suggested the possibility of an 
interaction between information concerning the probability of experiencing an adverse effect and 
provision of information on how to reduce the risk of experiencing the effect.  Consistent with 
study hypotheses, provision of risk prevention information reduced the effect of variation in the 
probability of the adverse effect (i.e., 5% versus 20%) on both willingness to use the medication 
and perceived medication safety. These findings must be interpreted cautiously. However, they 
underscore the need for research that attempts to better understand how communication about 
different risk dimensions (e.g., probability, severity, controllability) interact with one another. It 
is also important to examine the effect of preexisting beliefs on risk information processing. In 
the same way that individuals have mental representations of illnesses,40 they also have mental 
representations of treatment options, including medications.32-35 Research suggests that judgment 
and decision making is influenced most by those memory representations that are activated by 
characteristics of the decision-making context (e.g., environmental cues).21 Thus, it seems likely 
that the impact of medication risk communications depends on a combination of (1) the 
information explicitly provided and (2) individuals’ preexisting mental representations, rather 
than either of these factors in isolation. 
Finally, individuals who were told that the risk of fungal infection was 20% rated the 
medication as less likely to help than individuals in the other two groups. Although unexpected, 
this finding is consistent with previous research that has demonstrated an inverse association 
between perceived risk and perceived benefits.31  
Limitations 
This study has several limitations that should be noted. First, real patients were not 
studied. Participants were recruited through a crowdsourcing internet marketplace and most were 
fairly young, relatively healthy, and well-educated. Thus, the generalizability of the study 
findings to a more typical patient population remains open to question. Second, participants read 
a hypothetical scenario that provided a limited amount of information. In an actual counseling 
session, pharmacists have the opportunity to tailor information on the basis of patient 
characteristics and patients have the chance to ask questions if information the pharmacist 
provides is unclear. In addition, non-verbal communication can facilitate patient understanding, 
and the study methods did not allow for this type of effect. Finally, there may be differences 
among participant characteristics that influence risk perception and associated behaviors, such as 
tendency towards risk aversion, numeracy, and literacy skills. These were not assessed in this 
study. 
Conclusion 
Despite these limitations, the findings suggest that optimal risk communication involves 
far more than simply informing patients about possible adverse effects. Providing patients with a 
numerical estimate of the probability of experiencing specific adverse effects may reduce 
overestimation of risk probability and lead to greater acceptance of therapy and long-term 
adherence. But, counseling patients about strategies they can implement to reduce the risk of 
adverse effects may be equally or more important. Further research is needed to examine the 
effect of adverse effect counseling on medication adherence, ideally within the context of real 
life clinical encounters. Ultimately, helping patients understand how to minimize medication 
risks may increase patient acceptance of therapeutic recommendations and lead to improved 
health outcomes. 
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Table 1. Additional Information Presented to Participants in Scenario Depending on 
Experimental Condition 
 
Probability 
Prevention Strategy 
No Information Prevention Strategy 
Only 
Prevention Strategy Plus 
Explanation 
 
No 
Information 
─ He says that these 
infections can be 
prevented by rinsing 
your mouth out with 
cool water after you 
use it. 
He says when the medication is 
inhaled, some of it gets stuck in 
the back of your throat and allows 
fungi to grow. Rinsing with water 
removes any of the medication 
stuck in your throat. 
 
 
 
 
Low 
 
 
He says that these 
infections occur 
in about 5% of 
people who use 
Cradulox. 
 
He says that these 
infections occur in 
about 5% of people 
who use Cradulox, 
but they can be 
prevented by rinsing 
your mouth out with 
cool water after you 
use it. 
He says that these infections occur 
in about 5% of people who use 
Cradulox, but they can be 
prevented by rinsing your mouth 
out with cool water after you use 
it. He says when the medication is 
inhaled, some of it gets stuck in 
the back of your throat and allows 
fungi to grow. Rinsing with water 
removes any of the medication 
stuck in your throat. 
 
 
 
 
High 
 
 
He says that these 
infections occur 
in about 20% of 
people who use 
Cradulox. 
 
He says that these 
infections occur in 
about 20% of people 
who use Cradulox, 
but they can be 
prevented by rinsing 
your mouth out with 
cool water after you 
use it. 
He says that these infections occur 
in about 20% of people who use 
Cradulox, but they can be 
prevented by rinsing your mouth 
out with cool water after you use 
it. He says when the medication is 
inhaled, some of it gets stuck in 
the back of your throat and allows 
fungi to grow. Rinsing with water 
removes any of the medication 
stuck in your throat. 
 
 
 
 
 
 
 
 
Table 2. Means (SE) for Outcome Variables by Type of Probability Information Received. 
Outcome Variable No Probability Low Probability High Probability 
 
Likely to Take 
Medication 
 
4.77 (1.46)a 4.95 (1.36)a 4.21 (1.59)b 
Medication 
Safety 
 
4.19 (1.16)a 4.42 (1.04)b 3.82 (1.19)c 
Medication Benefits 
Outweigh Risks 
 
4.56 (1.37)a 4.79 (1.33)a 4.19 (1.39)b 
Medication Likely  
to Help 
 
5.05 (0.90)a 5.11 (0.88)a 4.87 (0.95)b 
Medication Likely to 
Cause Side Effects 
 
2.69 (1.36)a 1.73 (1.38)b 2.95 (1.32)a 
Likely to Recommend 
Medication 
 
3.52 (1.51)a 3.89 (1.39)b 3.25 (1.59)a 
______________________________________________________________________________ 
Note: For each outcome variable, superscripts (a, b, c) are used to indicate which groups (i.e., No 
Probability, Low Probability, High Probability) differed from one another at p ≤ 0.05. For each 
outcome variable, the means for groups that share a common superscript are not statistically 
different (i.e., p > 0.05). In contrast, the means for groups that have different superscripts are 
statistically different (i.e., p ≤ 0.05).  
 
 
 
 
 
 
 
 
 
 
  
Table 3. Means (SE) for Outcome Variables by Type of Prevention Information Received. 
 
Outcome Variable 
 
No Prevention 
Information 
 
Prevention 
Information 
Prevention 
Information and 
Rationale 
 
Likely to Take 
Medication 
 
4.23 (1.67)a 4.94 (1.27)b 4.75 (1.47)b 
Medication 
Safety 
 
3.85 (1.19)a 4.40 (1.05)b 4.17 (1.16)c 
Medication Benefits 
Outweigh Risks 
 
4.11 (1.46)a 4.71 (1.24)b 4.70 (1.38)b 
Medication Likely  
to Help 
 
4.90 (0.93)a 5.06 (0.86)a 5.06 (0.94)a 
Medication Likely to 
Cause Side Effects 
 
2.48 (1.42)a 2.39 (1.48)a 2.48 (1.45)a 
Likely to Recommend 
Medication 
 
3.21 (1.59)a 3.72 (1.47)b 3.74 (1.44)b 
______________________________________________________________________________ 
Note: For each outcome variable, superscripts (a, b, c) are used to indicate which groups (i.e., No 
Prevention Information, Prevention Information, Prevention Information and Rationale) differed 
from one another at p ≤ 0.05. For each outcome variable, the means for groups that share a common 
superscript are not statistically different (i.e., p > 0.05). In contrast, the means for groups that have 
different superscripts are statistically different (i.e., p ≤ 0.05).  
 
 
 
  
Table 4. Most Important Reasons (%) for Willingness to Take Medication 
   
 Type of Probability Information 
Received 
Type of Prevention Information 
Received 
 
 
Reason 
 
 
 
No 
Probability 
(N = 202) 
 
 
Low 
Probability 
(N = 206) 
 
 
High 
Probability 
(N = 193) 
 
No 
Prevention 
Information 
(N = 191) 
 
 
Prevention 
Information 
(N = 209) 
Prevention 
Information 
and 
Explanation  
(N = 201) 
 
The adverse 
events are not 
very serious 
 
13.4a 7.8a 8.3a 3.1a 10.1b 15.9c 
Any serious 
adverse events 
are unlikely 
 
21.8a 33.0b 18.6a 22.5a 29.2a 21.9a 
Prefer to avoid 
taking 
medications 
 
9.4a 8.2a 9.8a 7.3a 8.1a 11.9a 
A lot of people 
will get fungal 
infections 
 
9.9a 6.8a 19.7b 20.4a 7.7b 8.5b 
Would like to 
get rid of 
wheezing and 
shortness of 
breath 
 
43.6a 42.7a 42.5a 44.0a 44.0 a 40.8a 
None of the 
above 
2.0a 1.5a 1.0a 2.6a 1.0a 1.0a 
______________________________________________________________________________  
Note: This table presents the percentage of participants who endorsed different reasons for either taking or 
not taking the hypothetical medication stratified by the two experimental conditions: Type of Probability 
Information Received and Type of Prevention Information Received. Within each condition, superscripts 
(a, b, c) are used to indicate which specific groups (e.g., No Probability versus Low Probability, No 
Probability versus High Probability, Low versus High Probability) differed from one another at p ≤ 0.05. 
For each reason, differences between groups that share a common superscript are not statistically significant 
(i.e., p > 0.05); whereas, differences between groups that have different superscripts are statistically 
significant (i.e., p ≤ 0.05).  
 
Figure 1. Interaction of Probability and Prevention Strategy Information 
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